AR017852A1 - COMPUESTOS DE PIRAZOLO (3,4-b)PIRIDINA Y SUS SALES, UTILES COMO INHIBIDORES DE LAS PROTEINA-QUINASAS DEPENDIENTES DE CICLINA, Y LAS COMPOSICIONESFARMACEUTICAS QUE LOS CONTIENEN, EVENTUALMENTE ASOCIADOS CON UN AGENTE ANTICANCER. - Google Patents
COMPUESTOS DE PIRAZOLO (3,4-b)PIRIDINA Y SUS SALES, UTILES COMO INHIBIDORES DE LAS PROTEINA-QUINASAS DEPENDIENTES DE CICLINA, Y LAS COMPOSICIONESFARMACEUTICAS QUE LOS CONTIENEN, EVENTUALMENTE ASOCIADOS CON UN AGENTE ANTICANCER.Info
- Publication number
- AR017852A1 AR017852A1 ARP980106323A ARP980106323A AR017852A1 AR 017852 A1 AR017852 A1 AR 017852A1 AR P980106323 A ARP980106323 A AR P980106323A AR P980106323 A ARP980106323 A AR P980106323A AR 017852 A1 AR017852 A1 AR 017852A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- agent
- compounds
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se revelan compuestos de formula (I) y las sales farmacéuticamente aceptables del mismo para uso como inhibidores de cinasas dependientes deciclina, en donde: X es oxígeno, azufre, sulfoxido o sulfona; Y es alquilo, arilo, alquilarilo, heteroarilo, alquilheteroarilo, cicloalquilo,alquilcicloalquilo, heterocicloalquilo, alquilheterocicloalquilo; R1 es hidrogeno o alquilo inferior; R2 es alquilo, arilo, alquilarilo, heteroarilo,alquilheteroarilo, cicloalquilo, alquilcicloalquilo, heterocicloalquilo, alquilheterocicloalquilo,-o-alquilo, -o-aril, NR4R5; R3 es hidrogeno o alquiloinferior; R4 es hidrogeno, alquilo, arilo, alquilarilo, heteroarilo, alquilheteroarilo, cicloalquilo, alquilcicloalquilo, heterocicloalquilo, alquilheterocicloalquilo, -o-alquilo, -o-arilo; y R5 es hidrogeno, alquilo, arilo, alquilarilo, heteroarilo, alquilheteroarilo, cicloalquilo, alquilcicloalquilo,heterocicloalquilo, alquilheterocicloalquilo, -o-alquilo, -o-arilo, teniendo las definiciones precedentes el siguiente alcance: alquilo C1-12, cicloalquiloy arilo C3-15, heterocicloalquilo y heteroarilo C3-15 sustituidos por uno a tres heteroátomos elegidos entre el O, S o N. Los compuestos de la formula (I)son inhibidores de las proteínas cinasas y son utiles enel tratamiento de enfermedades proliferativas, por ejemplo, cáncer, inflamacion y artritis.También podrían ser utiles en el tratamiento de enfermedad de Alzheimer. También se revelan las composicion que contienen dichos compuestos de formula(I).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6963397P | 1997-12-13 | 1997-12-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR017852A1 true AR017852A1 (es) | 2001-10-24 |
Family
ID=22090219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP980106323A AR017852A1 (es) | 1997-12-13 | 1998-12-11 | COMPUESTOS DE PIRAZOLO (3,4-b)PIRIDINA Y SUS SALES, UTILES COMO INHIBIDORES DE LAS PROTEINA-QUINASAS DEPENDIENTES DE CICLINA, Y LAS COMPOSICIONESFARMACEUTICAS QUE LOS CONTIENEN, EVENTUALMENTE ASOCIADOS CON UN AGENTE ANTICANCER. |
Country Status (11)
Country | Link |
---|---|
US (1) | US6107305A (es) |
EP (1) | EP1043998B1 (es) |
JP (1) | JP2002508324A (es) |
AR (1) | AR017852A1 (es) |
AT (1) | ATE355841T1 (es) |
AU (1) | AU747705C (es) |
CA (1) | CA2314355A1 (es) |
DE (1) | DE69837282T2 (es) |
ES (1) | ES2281941T3 (es) |
WO (1) | WO1999030710A1 (es) |
ZA (1) | ZA9811178B (es) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ338108A (en) * | 1997-03-03 | 2004-12-24 | Univ Texas | Suppression of cyclin kinase 2 activity for prevention and treatment of DNA viral infections using roscovitine and olomoucine |
US6407103B2 (en) | 1998-04-21 | 2002-06-18 | Bristol-Myers Squibb Pharma Company | Indeno [1,2-c] pyrazol-4-ones and their uses |
US6326379B1 (en) * | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
US20040048844A1 (en) * | 1999-10-20 | 2004-03-11 | Bristol-Myers Squibb Pharma Company | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents |
US6291504B1 (en) | 1999-10-20 | 2001-09-18 | Dupont Pharmaceuticals Company | Acylsemicarbazides and their uses |
FR2806626B1 (fr) * | 2000-03-22 | 2003-11-28 | Centre Nat Rech Scient | Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues |
JP2004507455A (ja) | 2000-04-25 | 2004-03-11 | ブリストル−マイヤーズ スクイブ カンパニー | サイクリン依存性キナーゼ阻害剤としての、5−チオ−、スルフィニル−およびスルホニルピラゾロ[3,4−b]−ピリジンの用途 |
WO2001082967A1 (en) * | 2000-04-28 | 2001-11-08 | Yamanouchi Pharmaceutical Co., Ltd. | MEDICINAL COMPOSITIONS FOR SUPPRESSING β-AMYLOID PRODUCTION |
KR100423899B1 (ko) * | 2000-05-10 | 2004-03-24 | 주식회사 엘지생명과학 | 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸 |
PE20020394A1 (es) * | 2000-08-18 | 2002-06-21 | Agouron Pharma | Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2 |
AU2001279090A1 (en) | 2000-08-18 | 2002-03-04 | Agouron Pharmaceuticals, Inc. | Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting protein kinases |
AU2002213132A1 (en) * | 2000-10-10 | 2002-04-22 | Board Of Regents, The University Of Texas System | Suppression of cyclin kinase activity for prevention and treatment of infections |
US6706718B2 (en) * | 2000-12-01 | 2004-03-16 | Bristol-Myers Squibb Company | 3-(2,4-dimethylthiazol-5-yl)indeno[1,2-c]pyrazol-4-one derivatives and their uses |
US6849631B2 (en) | 2000-12-08 | 2005-02-01 | Bristol Myers Squibb Pharma Company | Semicarbazides and their uses |
US6977262B2 (en) * | 2001-02-02 | 2005-12-20 | Mitsubishi Pharma Corporation | Dihydropyrazolopyridine compounds and pharmaceutical use thereof |
AU2002342878A1 (en) * | 2001-05-16 | 2002-11-25 | Axxima Pharmaceuticals Ag | Pyridylpyrimidine derivatives as effective compounds against prion diseases |
JP3896309B2 (ja) | 2001-07-09 | 2007-03-22 | ファイザー株式会社 | プロテインキナーゼc阻害物質としてのピラゾロキノリノン誘導体 |
ES2292812T3 (es) * | 2001-10-19 | 2008-03-16 | Ortho-Mcneil Pharmaceutical, Inc. | 2-fenil benzimidazol e imidazo-(4,5)-piridinas como inhibidores de cds1/chk2 y coadyuvantes para quimioterapia o radioterapia en el tratamiento del cancer. |
US7582670B2 (en) | 2001-12-13 | 2009-09-01 | Natrogen Therapeutics, Inc. | Methods of treating an inflammatory-related disease |
US20100098702A1 (en) | 2008-09-16 | 2010-04-22 | Longgui Wang | Method of treating androgen independent prostate cancer |
US20050154046A1 (en) * | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
US8748475B2 (en) | 2004-01-12 | 2014-06-10 | Natrogen Therapeutics International, Inc. | Methods and compositions for treating lupus |
GB0218625D0 (en) * | 2002-08-10 | 2002-09-18 | Astex Technology Ltd | Pharmaceutical compounds |
US8673924B2 (en) * | 2002-09-04 | 2014-03-18 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
AU2003263071B2 (en) * | 2002-09-04 | 2007-03-15 | Merck Sharp & Dohme Llc | Pyrazolopyrimidines as cyclin-dependent kinase inhibitors |
US7196078B2 (en) * | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
DE60332846D1 (de) * | 2002-09-04 | 2010-07-15 | Pharmacopeia Llc | Zur behandlung von krebserkrankungen geeignete pyrazolopyrimidine |
CN1880317B (zh) * | 2002-09-04 | 2012-10-10 | 先灵公司 | 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并嘧啶 |
US7161003B1 (en) * | 2002-09-04 | 2007-01-09 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US8580782B2 (en) * | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
US7151104B2 (en) * | 2002-09-19 | 2006-12-19 | Schering Corporation | Pyrazolopyridines as cyclin dependent kinase inhibitors |
ATE481402T1 (de) * | 2003-02-27 | 2010-10-15 | Palau Pharma Sa | Pyrazolopyridin-derivate |
US7132440B2 (en) | 2003-04-17 | 2006-11-07 | Janssen Pharmaceutica, N.V. | Substituted benzimidazoles and imidazo-[4,5]-pyridines |
FR2857363B1 (fr) * | 2003-07-10 | 2007-09-07 | Aventis Pharma Sa | 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c] pyridines substituees compositions les contenant et utilisation |
AR045037A1 (es) * | 2003-07-10 | 2005-10-12 | Aventis Pharma Sa | Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion. |
US7405220B2 (en) * | 2004-06-09 | 2008-07-29 | Hoffmann-La Roche Inc. | Pyrazolopyrimidines |
CA2584493A1 (en) | 2004-06-18 | 2006-01-05 | Gpc Biotech, Inc. | Kinase inhibitors for treating cancers |
ATE432921T1 (de) | 2004-12-23 | 2009-06-15 | Gpc Biotech Ag | Quadratsäurederivate mit antiproliferativer wirkung |
KR20080020638A (ko) * | 2005-06-27 | 2008-03-05 | 사노피-아벤티스 | β-아드레날린 수용체 키나제 1의 억제제로서의피라졸로피리딘 유도체 |
RS51351B (en) * | 2005-07-20 | 2011-02-28 | Aventis Pharma S.A. | 1,4-DIHYDROPYRIDINE-CONDENSED HTEROCYCLES, PROCEDURES FOR THEIR PRODUCTION, USE AND THE COMPOSITIONS CONTAINING THEM |
ES2349476T3 (es) * | 2005-09-09 | 2011-01-03 | Schering Corporation | Nuevos derivados de 4-ciano, 4-amino y 4-aminometilo de compuestos de pirazolo[1,5-a]piridinas, pirazolo[1,5-c]pirimidinas y 2h-indazol y derivados de 5-ciano, 5-amino y 5-aminometilo de compuestos de imidazo[1,2-a]piridinas e imidazo[1,5-a]pirazinas, como inhibidores de cinasa dependiente de ciclina. |
CA2624882C (en) | 2005-10-06 | 2014-05-20 | Schering Corporation | Pyrazolopyrimidines as protein kinase inhibitors |
CN101370811A (zh) * | 2005-11-10 | 2009-02-18 | 先灵公司 | 作为蛋白激酶抑制剂的咪唑并吡嗪化合物 |
US7705009B2 (en) * | 2005-11-22 | 2010-04-27 | Hoffman-La Roche Inc. | 4-aminopyrimidine-5-thione derivatives |
BRPI0708615A2 (pt) | 2006-03-07 | 2011-06-07 | Array Biopharma Inc | compostos de pirazol heterobicìclicos e métodos de uso |
US20090175852A1 (en) | 2006-06-06 | 2009-07-09 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
EP1914234A1 (en) * | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors |
MX2009004791A (es) * | 2006-10-31 | 2009-08-19 | Schering Corp | Derivados de anilinopiperazina t metodos de uso de los mismos. |
AU2007314342B2 (en) | 2006-10-31 | 2013-02-21 | Merck Sharp & Dohme Corp. | Anilinopiperazine Derivatives and methods of use thereof |
JP5103604B2 (ja) * | 2006-10-31 | 2012-12-19 | メルク・シャープ・アンド・ドーム・コーポレーション | プロテインキナーゼ阻害剤としての2−アミノチアゾール−4−カルボン酸アミド |
US8450348B2 (en) * | 2007-02-21 | 2013-05-28 | Forma Tm, Llc | Derivatives of squaric acid with anti-proliferative activity |
US20100210700A1 (en) | 2007-05-08 | 2010-08-19 | Schering Corporation | Methods of treatment using intravenous formulations comprising temozolomide |
JP2011513331A (ja) | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | ピラゾール[3,4−b]ピリジンRAF阻害剤 |
EP2112150B1 (en) | 2008-04-22 | 2013-10-16 | Forma Therapeutics, Inc. | Improved raf inhibitors |
EP2112152A1 (en) | 2008-04-22 | 2009-10-28 | GPC Biotech AG | Dihydropteridinones as Plk Inhibitors |
WO2011000566A2 (en) * | 2009-06-30 | 2011-01-06 | Savira Pharmaceuticals Gmbh | Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections |
WO2011025706A2 (en) | 2009-08-26 | 2011-03-03 | Schering Corporation | Heterocyclic amide compounds as protein kinase inhibitors |
EP2325185A1 (en) | 2009-10-28 | 2011-05-25 | GPC Biotech AG | Plk inhibitor |
HU0900798D0 (en) | 2009-12-21 | 2010-03-01 | Vichem Chemie Kutato Kft | 4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity |
RU2011122942A (ru) | 2011-06-08 | 2012-12-20 | Общество С Ограниченной Ответственностью "Асинэкс Медхим" | Новые ингибиторы киназ |
US20150051227A1 (en) | 2012-03-30 | 2015-02-19 | Merck Sharp & Dohme Corp. | Predictive biomarker useful for cancer therapy mediated by a cdk inhibitor |
JP6434614B2 (ja) * | 2014-08-22 | 2018-12-05 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | インダゾール |
EP3712127A1 (en) | 2019-03-22 | 2020-09-23 | Deutsches Krebsforschungszentrum | Novel inhibitors of histone deacetylase 10 |
JP2022524887A (ja) | 2019-03-22 | 2022-05-10 | ドイチェス クレブスフォルシュングスツェントルム | ヒストンデアセチラーゼ10の新規の阻害剤 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1923990C3 (de) * | 1969-05-10 | 1978-11-23 | Bayer Ag | Verfahren zur Herstellung von N-substituierten M-Dihydropyridin-S.S-dicarbonsäureestern |
BE787249A (fr) * | 1971-08-05 | 1973-02-05 | Squibb & Sons Inc | Derives amino d'acides pyrazolopyridine carboxyliques, leurs esters et les sels de ces composes, ainsi que leurs procedes de preparation |
US3810905A (en) * | 1971-11-04 | 1974-05-14 | Squibb & Sons Inc | Pyrazolo(3,4-b)pyridine-5-carboxamides |
US3773778A (en) * | 1972-01-24 | 1973-11-20 | Squibb & Sons Inc | Sulfur derivatives of pyrazolo (3,4-b)pyridines |
US3987051A (en) * | 1975-04-16 | 1976-10-19 | E. R. Squibb & Sons, Inc. | Method for producing 1-unsubstituted pyrazolo[3,4-b]pyridine ketones |
US3985757A (en) * | 1975-09-17 | 1976-10-12 | E. R. Squibb & Sons, Inc. | Pyrazolopyridine ketones |
US4552883A (en) * | 1982-06-15 | 1985-11-12 | Ici Americas Inc. | Pyrazolo[3,4-b]pyridine carboxylic acid esters and their pharmaceutical use |
US5733920A (en) * | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
-
1998
- 1998-12-07 ZA ZA9811178A patent/ZA9811178B/xx unknown
- 1998-12-07 EP EP98960781A patent/EP1043998B1/en not_active Expired - Lifetime
- 1998-12-07 DE DE69837282T patent/DE69837282T2/de not_active Expired - Lifetime
- 1998-12-07 ES ES98960781T patent/ES2281941T3/es not_active Expired - Lifetime
- 1998-12-07 AU AU16297/99A patent/AU747705C/en not_active Ceased
- 1998-12-07 JP JP2000538693A patent/JP2002508324A/ja not_active Withdrawn
- 1998-12-07 AT AT98960781T patent/ATE355841T1/de not_active IP Right Cessation
- 1998-12-07 WO PCT/US1998/025920 patent/WO1999030710A1/en active IP Right Grant
- 1998-12-07 CA CA002314355A patent/CA2314355A1/en not_active Abandoned
- 1998-12-11 AR ARP980106323A patent/AR017852A1/es unknown
- 1998-12-11 US US09/209,575 patent/US6107305A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ZA9811178B (en) | 2000-06-07 |
DE69837282D1 (de) | 2007-04-19 |
ES2281941T3 (es) | 2007-10-01 |
EP1043998A1 (en) | 2000-10-18 |
AU747705C (en) | 2004-09-23 |
EP1043998A4 (en) | 2004-02-04 |
EP1043998B1 (en) | 2007-03-07 |
JP2002508324A (ja) | 2002-03-19 |
WO1999030710A1 (en) | 1999-06-24 |
CA2314355A1 (en) | 1999-06-24 |
ATE355841T1 (de) | 2007-03-15 |
US6107305A (en) | 2000-08-22 |
AU747705B2 (en) | 2002-05-23 |
AU1629799A (en) | 1999-07-05 |
DE69837282T2 (de) | 2007-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR017852A1 (es) | COMPUESTOS DE PIRAZOLO (3,4-b)PIRIDINA Y SUS SALES, UTILES COMO INHIBIDORES DE LAS PROTEINA-QUINASAS DEPENDIENTES DE CICLINA, Y LAS COMPOSICIONESFARMACEUTICAS QUE LOS CONTIENEN, EVENTUALMENTE ASOCIADOS CON UN AGENTE ANTICANCER. | |
AR017182A1 (es) | Compuestos de aminotiazol, inhibidores de las kinasas dependientes de ciclinas y las composiciones farmaceuticas que los contienen. | |
AR031680A1 (es) | Utilizacion de acrilamidas de quinuclidina para la preparacion de medicamentos, compuestos y composicion farmaceutica | |
UY28157A1 (es) | Miméticos de glucocorticoides métodos para su elaboración composiciones farmacéuticas y sus usos | |
PE20010211A1 (es) | Compuestos de tiazol y composiciones farmaceuticas para inhibir las quinasas de proteina | |
UY27976A1 (es) | Piperazinas heterocíclicas sustituídas para el tratamiento de la esquizofrenia | |
PA8550101A1 (es) | Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células, y métodos para su utilización | |
AR048642A1 (es) | Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento | |
AR037534A1 (es) | Derivado de adamantano, su uso en la fabricacion de un medicamento para usar en terapia, composicion farmaceutica, proceso para la preparacion de dicho compuesto y dicha composicion y compuestos intermediarios | |
UY28526A1 (es) | Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos | |
PA8432901A1 (es) | Compuestos de piridilpirrol | |
TR200003429T2 (tr) | Hücresel çoğalma inhibitörleri olarak bisiklik pirimidinler ve bisiklik 3,4-dihidropirimidinler. | |
AR034858A1 (es) | Compuestos elevadores de abca-1,composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento | |
AR035669A1 (es) | Imidazoquinolinas y 6,7,8,9-tetrahidroimidazoquinolinas, composiciones que las comprenden, y usos de dichos compuestos en la preparacion de medicamentos | |
PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
ES2104572T3 (es) | N-aminocarbamatos afines a la fisostigmina, un procedimiento para su preparacion y su uso como medicamentos. | |
MX9300786A (es) | Compuestos hipolipidaemicos. | |
PE20090960A1 (es) | Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas | |
AR026974A1 (es) | N-[5-[[[5-alquil-2-oxazolil]metil]tio]-2-tiazolil]-carboxamidas, utiles como inhibidores de cinasas dependientes de ciclina, y las composicionesfarmaceuticas que los contienen | |
AR039689A1 (es) | Difenilazetidinonas sustituidas, medicamentos que comprenden estos compuestos y su uso | |
AR072510A1 (es) | Derivados de triazinas y de uracilos, su preparacion y su aplicacion en terapeutica humana | |
AP1477A (en) | Derivatives of purine, their preparation process and pharmaceutical compositions containing them. | |
AR036176A1 (es) | Un derivado de fenil-acetamido-tiazol, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un producto o kit que los comprende, y un metodo que utiliza dicho derivado | |
PE120099A1 (es) | Nueva 3,4-diariltiazolina-2-ona o 2-tiona derivados, sus metodos de preparacion y su uso terapeutico | |
AR044193A1 (es) | Compuesto de 1,2,4-triazol-5-ona, composicion farmaceutica que lo comprende, su uso para prepararla y kit que comprende dicho compuesto |